The global market for DNA damage response drugs is predicted to grow at a CAGR of 21.33% over the forecast period of 2020-2030. The market is driven by certain factors, which include the rising global prevalence of cancer, favorable reimbursement scenario, increasing oncology R&D expenditure, and an increase in the adoption of precision medicine in cancer treatment.

1. Global DNA Damage
Response Drugs
Market
Focus on Commercialized Drugs,
Potential Pipeline Drugs, Application,
Country Data (13 Countries), and
Competitive Landscape:
Analysis and Forecast: 2020-2030
August 2020
TOC
Analysis and Forecast: 2018-2023

2. Global DNA Damage Response Drugs Market
All rights reserved at BIS Research 2
BIS Research is a leading market intelligence and technology research company. BIS Research
publishes in-depth market intelligence reports focusing on the market estimations, technology
analysis, emerging high-growth applications, deeply segmented granular country-level market data
and other important market parameters useful in the strategic decision making for senior
management. BIS Research provides multi-client reports, company profiles, databases, and custom
research services.
Copyright © 2020 BIS Research
All Rights Reserved. This document contains highly confidential information and is the sole property
of BIS Research. Disclosing, copying, circulating, quoting or otherwise reproducing any or all contents
of this document is strictly prohibited. Access to this information is provided exclusively for the benefit
of the people or organization concerned. It may not be accessed by, or offered whether for sale or
otherwise to any third party.

3. Global DNA Damage Response Drugs Market
All rights reserved at BIS Research 3
Table of Contents
1. Product Definition ..............................................................................................32
1.1 Inclusion and Exclusion .............................................................................. 32
2. Research Scope..................................................................................................33
2.1 Scope of the Study....................................................................................... 33
2.2 Key Questions Answered in the Report..................................................... 34
3. Research Methodology ......................................................................................36
3.1 DNA Damage Response Drugs in Oncology: Research
Methodology................................................................................................. 36
3.2 Data Sources ................................................................................................ 37
3.2.1 Primary Data Sources ....................................................................... 37
3.2.2 Secondary Data Sources .................................................................. 38
3.3 Market Estimation Model............................................................................. 39
4. Market Overview.................................................................................................42
4.1 Introduction .................................................................................................. 42
4.2 Importance of DDR Pathways in Oncology................................................ 42
4.3 Key Strategies for Targeting DDR Pathways............................................. 43
4.4 DDR Drugs Commercialization Landscape................................................ 45
4.5 COVID-19 Impact on Oncology Clinical Research .................................... 46
4.6 Market Size and Growth Potential, $Million, 2019-2030 ............................ 47
4.6.1 North America.................................................................................... 47
4.6.2 Europe................................................................................................ 48
4.6.3 Asia-Pacific (APAC)........................................................................... 49
4.6.4 Latin America (LATAM)..................................................................... 50
4.6.5 Rest-of-the-World (RoW)................................................................... 51
5. Industry Insights.................................................................................................52
5.1 Overview ....................................................................................................... 52
5.2 Legal Requirements and Frameworks in the U.S...................................... 52
5.2.1 Clinical Trial Authorization ............................................................... 52

4. Global DNA Damage Response Drugs Market
All rights reserved at BIS Research 4
5.2.2 Marketing Authorization ................................................................... 52
5.2.3 Post-Authorization Regulations....................................................... 55
5.3 Legal Requirements and Frameworks in Europe ...................................... 55
5.3.1 Centralized Procedure ...................................................................... 56
5.3.2 Decentralized Procedure .................................................................. 56
5.3.3 Mutual-Recognition Procedure ........................................................ 56
5.3.4 National Procedure............................................................................ 57
5.4 Legal Requirements and Frameworks in Asia-Pacific .............................. 57
5.4.1 China .................................................................................................. 57
5.4.2 Japan.................................................................................................. 58
5.5 Patent Analysis ............................................................................................ 59
6. Market Dynamics................................................................................................61
6.1 Overview ....................................................................................................... 61
6.2 Impact Analysis............................................................................................ 61
6.3 Market Drivers .............................................................................................. 62
6.3.1 Rising Global Prevalence of Cancer................................................ 62
6.3.2 Favorable Regulatory Environment................................................. 63
6.3.3 Increasing Oncology R&D Expenditure........................................... 64
6.3.4 Increase in Adoption of Precision Medicine in Cancer
Treatment........................................................................................... 66
6.4 Market Restraints ......................................................................................... 67
6.4.1 High Cost Hindering the Adoption Rate .......................................... 67
6.4.2 Unfavorable Reimbursement Scenario............................................ 67
6.4.3 Safety Concerns Pertaining to Severe Adverse Effects................. 68
6.5 Market Opportunity ...................................................................................... 69
6.5.1 Massive scope in Emerging Regions .............................................. 69
7. Competitive Landscape .....................................................................................70
7.1 Key Strategies and Developments ............................................................. 70
7.1.1 Product Approvals and Other Activities.......................................... 71
7.1.2 Synergistic Activities ........................................................................ 72
7.1.3 Product Launch and Updradations.................................................. 73

5. Global DNA Damage Response Drugs Market
All rights reserved at BIS Research 5
7.1.4 Business Expansion and Funding................................................... 74
7.1.5 Mergers and Acquisitions................................................................. 75
7.2 Market Share Analysis, 2018-2019.............................................................. 76
7.3 Growth Share Analysis................................................................................ 78
8. Epidemiology Analysis for DNA Damage Response Drugs............................80
9. Clinical Landscape.............................................................................................86
9.1 By Phase of Development ........................................................................... 86
9.2 By DDR Pathway Target .............................................................................. 87
9.3 By Oncology Specialty ................................................................................ 88
10. Global DNA Damage Response Drugs Market, by Commercialized Drugs
($Million), 2019-2030...........................................................................................89
10.1 Overview ....................................................................................................... 89
10.2 Lynparza ....................................................................................................... 90
10.3 Talzenna........................................................................................................ 93
10.4 Zejula............................................................................................................. 95
10.5 Rubraca......................................................................................................... 98
11. DNA Damage Response Drugs, by Potential Pipeline Drugs .......................101
11.1 Overview ..................................................................................................... 101
11.2 PARP Inhibitor............................................................................................ 101
11.2.1 Phase III............................................................................................ 102
11.2.1.1 Pamiparib .......................................................................................... 102
11.2.1.2 Veliparib ............................................................................................ 103
11.2.1.3 Fluzoparib.......................................................................................... 104
11.2.2 Phase II............................................................................................. 106
11.2.3 Phase I.............................................................................................. 106
11.3 WEE1 Kinase Inhibitor............................................................................... 107
11.3.1 Phase I.............................................................................................. 107
11.4 ATR Kinase Inhibitor.................................................................................. 108
11.4.1 Phase II............................................................................................. 108

6. Global DNA Damage Response Drugs Market
All rights reserved at BIS Research 6
11.4.2 Phase I.............................................................................................. 108
11.5 Aurora B Kinase Inhibitor.......................................................................... 109
11.5.1 Phase II............................................................................................. 109
11.6 DNA-PK Inhibitors...................................................................................... 109
11.6.1 Phase II............................................................................................. 110
11.6.2 Phase I.............................................................................................. 110
11.7 Others.......................................................................................................... 110
11.7.1 Phase II............................................................................................. 111
11.7.2 Phase I.............................................................................................. 111
12. Global DNA Damage Response Drugs Market, by Application, ($Million),
2019-2030 ..........................................................................................................112
12.1 Overview ..................................................................................................... 112
12.2 Ovarian Cancer........................................................................................... 113
12.3 Breast Cancer............................................................................................. 118
12.4 Pancreatic Cancer...................................................................................... 121
12.5 Prostate Cancer.......................................................................................... 123
13. Global DNA Damage Response Drugs Market, by Region ($Million), 2019-
2030 ...................................................................................................................126
13.1 Overview ..................................................................................................... 126
13.2 North America ............................................................................................ 129
13.2.1 U.S. ................................................................................................... 132
13.2.2 Canada ............................................................................................. 134
13.3 Europe......................................................................................................... 136
13.3.1 Germany........................................................................................... 139
13.3.2 France............................................................................................... 140
13.3.3 U.K. ................................................................................................... 142
13.3.4 Italy ................................................................................................... 143
13.3.5 Spain................................................................................................. 145
13.3.6 Switzerland ...................................................................................... 146
13.3.7 Rest-of-Europe................................................................................. 148

7. Global DNA Damage Response Drugs Market
All rights reserved at BIS Research 7
13.4 Asia-Pacific................................................................................................. 149
13.4.1 China ................................................................................................ 152
13.4.2 Japan................................................................................................ 153
13.4.3 India.................................................................................................. 155
13.4.4 Australia........................................................................................... 156
13.4.5 Rest-of-APAC................................................................................... 158
13.5 Latin America ............................................................................................. 159
13.5.1 Brazil................................................................................................. 161
13.5.2 Rest-of-Latin America ..................................................................... 163
13.6 Rest-of-the-World....................................................................................... 164
14. Company Profiles.............................................................................................165
14.1 Overview ..................................................................................................... 165
14.2 AbbVie Inc................................................................................................... 166
14.2.1 Company Overview ......................................................................... 166
14.2.2 Role of AbbVie Inc. in Global DNA Damage Response Drugs
Market............................................................................................... 166
14.2.3 Financials......................................................................................... 168
14.2.4 Key Insights about Financial Health of the Company.................. 170
14.2.5 SWOT Analysis................................................................................ 171
14.3 AstraZeneca plc ......................................................................................... 172
14.3.1 Company Overview ......................................................................... 172
14.3.2 Role of AstraZeneca plc in Global DNA Damage Response
Drugs Market ................................................................................... 172
14.3.3 Financials......................................................................................... 176
14.3.4 Key Insights about Financial Health of the Company.................. 178
14.3.5 SWOT Analysis................................................................................ 179
14.4 Bayer AG..................................................................................................... 180
14.4.1 Company Overview ......................................................................... 180
14.4.2 Role of Bayer AG in Global DNA Damage Response Drugs
Market............................................................................................... 180
14.4.3 Financials......................................................................................... 181
14.4.4 Key Insight about Financial Health of the Company.................... 184

8. Global DNA Damage Response Drugs Market
All rights reserved at BIS Research 8
14.4.5 SWOT Analysis................................................................................ 185
14.5 BeiGene, Ltd............................................................................................... 186
14.5.1 Company Overview ......................................................................... 186
14.5.2 Role of BeiGene, Ltd. in Global DNA Damage Response
Drugs Market ................................................................................... 186
14.5.3 Financials......................................................................................... 188
14.5.4 Key Insights about Financial Health of the Company.................. 190
14.5.5 SWOT Analysis................................................................................ 191
14.6 Clovis Oncology......................................................................................... 192
14.6.1 Company Overview ......................................................................... 192
14.6.2 Role of Clovis Oncology in Global DNA Damage Response
Drugs Market ................................................................................... 192
14.6.3 Financials......................................................................................... 194
14.6.4 Key Insights about Financial Health of the Company.................. 195
14.6.5 SWOT Analysis................................................................................ 196
14.7 Debiopharm International SA.................................................................... 197
14.7.1 Company Overview ......................................................................... 197
14.7.2 Role of Debiopharm International SA in Global DNA Damage
Response Drugs Market ................................................................. 197
14.7.3 SWOT Analysis................................................................................ 199
14.8 Eli Lilly & Company.................................................................................... 200
14.8.1 Company Overview ......................................................................... 200
14.8.2 Role of Eli Lilly & Company in Global DNA Damage
Response Drugs Market ................................................................. 200
14.8.3 Financials......................................................................................... 201
14.8.4 Key Insights about Financial Health of the Company.................. 203
14.8.5 SWOT Analysis................................................................................ 204
14.9 GlaxoSmithKline plc .................................................................................. 205
14.9.1 Company Overview ......................................................................... 205
14.9.2 Role of GlaxoSmithKline plc in Global DNA Damage
Response Drugs Market ................................................................. 205
14.9.3 Financials......................................................................................... 207
14.9.4 Key Insights about Financial Health of the Company.................. 209

9. Global DNA Damage Response Drugs Market
All rights reserved at BIS Research 9
14.9.5 SWOT Analysis................................................................................ 210
14.10 Merck KGaA................................................................................................ 211
14.10.1 Company Overview ......................................................................... 211
14.10.2 Role of Merck KGaA in Global DNA Damage Response
Drugs Market ................................................................................... 211
14.10.3 Financials......................................................................................... 213
14.10.4 Key Insights about Financial Health of the Company.................. 215
14.10.5 SWOT Analysis................................................................................ 216
14.11 NMS Group S.p.A ....................................................................................... 217
14.11.1 Company Overview ......................................................................... 217
14.11.2 Role of NMS Group S.p.A in Global DNA Damage Response
Drugs Market ................................................................................... 217
14.11.3 SWOT Analysis................................................................................ 219
14.12 Onxeo SA.................................................................................................... 220
14.12.1 Company Overview ......................................................................... 220
14.12.2 Role of Onxeo SA in Global DNA Damage Response Drugs
Market............................................................................................... 220
14.12.3 Financials......................................................................................... 222
14.12.4 Key Insights about Financial Health of the Company.................. 224
14.12.5 SWOT Analysis................................................................................ 225
14.13 Pfizer Inc. .................................................................................................... 226
14.13.1 Company Overview ......................................................................... 226
14.13.2 Role of Pfizer Inc. in Global DNA Damage Response Drugs
Market............................................................................................... 226
14.13.3 Financials......................................................................................... 228
14.13.4 Key Insights about Financial Health of the Company.................. 232
14.13.5 SWOT Analysis................................................................................ 233
14.14 Repare Therapeutics.................................................................................. 234
14.14.1 Company Overview ......................................................................... 234
14.14.2 Role of Repare Therapeutics in Global DNA Damage
Response Drugs Market ................................................................. 234
14.14.3 SWOT Analysis................................................................................ 236
14.15 Sierra Oncology, Inc. ................................................................................. 237

10. Global DNA Damage Response Drugs Market
All rights reserved at BIS Research 10
14.15.1 Company Overview ......................................................................... 237
14.15.2 Role of Sierra Oncology, Inc. in Global DNA Damage
Response Drugs Market ................................................................. 237
14.15.3 Financials......................................................................................... 239
14.15.4 Key Insights about Financial Health of the Company.................. 240
14.15.5 SWOT Analysis................................................................................ 241
14.16 Zentalis Pharmaceuticals, LLC ................................................................. 242
14.16.1 Company Overview ......................................................................... 242
14.16.2 Role of Zentalis Pharmaceuticals, LLC in Global DNA
Damage Response Drugs Market................................................... 242
14.16.3 SWOT Analysis................................................................................ 244

11. Global DNA Damage Response Drugs Market
All rights reserved at BIS Research 11
List of Figures
Figure 1: Global Prevalence of Prostate and Breast Cancer, 2012-2017.........................................21
Figure 2: Steps for Obtaining Marketing Authorization in the U.S. ...................................................22
Figure 3: Clinical Landscape of DNA Damage Response Drugs, by Phase of Development ..........23
Figure 4: Clinical Landscape of DNA Damage Response Drugs, by Pathway Target .....................24
Figure 5: Implications of COVID-19 on Cancer Clinical Trials: Short- and Long-Term
Implications..........................................................................................................................25
Figure 6: Global Target Population of DNA Damage Response Drugs, 2020-2030.........................26
Figure 7: Impact Analysis of Market Drivers and Market Challenges on the Global DNA
Damage Response Drugs Market........................................................................................27
Figure 8: Global DNA Damage Response Drugs Market, by Commercialized Drugs, 2019
vs. 2030 ($Million)................................................................................................................28
Figure 9: Expected Revenue of DNA Damage Response Drugs, by Potential Pipeline Drugs,
2025 vs. 2030......................................................................................................................29
Figure 10: Global DNA Damage Response Drugs Market, by Application, 2019 vs. 2030
($Million) ..............................................................................................................................30
Figure 11: Global DNA Damage Response Drugs Market Snapshot...............................................31
Figure 2.1: Global DNA Damage Response Drugs Market Segmentation.......................................33
Figure 3.1: Global DNA Damage Response Drugs Market: Research Methodology.......................36
Figure 3.2: Bottom-up Approach (Segment-Wise Analysis).............................................................39
Figure 3.3: Top-Down Approach (Segment-Wise Analysis).............................................................40
Figure 4.1: Underlying Pathway of DNA Damage and Repair .........................................................43
Figure 4.2: Implications of COVID-19 on Cancer Clinical Trials: Short- and Long-Term
Implications..........................................................................................................................47
Figure 4.3: North America DNA Damage Response Drugs Market, 2019 and 2030........................48
Figure 4.4: Europe DNA Damage Response Drugs Market, 2019-2030 .........................................49
Figure 4.5: Asia-Pacific DNA Damage Response Drugs Market, 2019-2030 ..................................50
Figure 4.6: Latin America DNA Damage Response Drugs Market, 2019-2030 ...............................51
Figure 5.1: Steps for Obtaining Marketing Authorization..................................................................53
Figure 5.2: Share of Patents (by Ownership), 2016-2019................................................................60

12. Global DNA Damage Response Drugs Market
All rights reserved at BIS Research 12
Figure 6.1: Global Prevalence of Breast, Prostate, and Ovarian Cancer, 2013-2017 ......................62
Figure 7.1: Share of Key Developments and Strategies, January 2016 – May 2020.......................71
Figure 7.2: Product Approvals and Other Activities Share (by Company), January 2016 –
May 2020.............................................................................................................................72
Figure 7.3: Synergistic Activities Share (by Company), January 2016 – May 2020 .........................73
Figure 7.4: Product Launch and Upgradations Share (by Company), January 2016 – May
2020.....................................................................................................................................74
Figure 7.5: Business Expansion and Funding Share (by Company), January 2016 – May
2020.....................................................................................................................................75
Figure 7.6: Mergers and Acquisitions Share (by Company), January 2016 – May 2020 .................76
Figure 7.7: Market Share Analysis for Global DNA Damage Response Drugs Market, 2018
and 2019..............................................................................................................................77
Figure 7.8: Growth-Share Analysis for Global DNA Damage Response Drugs Market, (by
Companies), 2019 ...............................................................................................................78
Figure 8.1: Global Prevalence of Ovarian Cancer (2012-2017) .......................................................81
Figure 8.2: Global Prevalence of Breast Cancer (2012-2017) .........................................................81
Figure 8.3: Global Prevalence of Prostate Cancer (2012-2017) ......................................................82
Figure 8.4: Global Prevalence of Pancreatic Cancer (2012-2017)...................................................82
Figure 8.5: Global Target Population of Ovarian Cancer (2020-2030).............................................83
Figure 8.6: Global Target Population of Breast Cancer (2020-2030)...............................................84
Figure 8.7: Global Target Population of Pancreatic Cancer (2020-2030).........................................84
Figure 8.8: Global Target Population of Prostate Cancer (2020-2030) ............................................85
Figure 9.1: DNA Damage Response Drugs: Developmental Phases ..............................................86
Figure 9.2: DNA Damage Response Drugs, by Pathway Target .....................................................87
Figure 9.3: DNA Damage Response Drugs: by Oncology Specialty................................................88
Figure 10.1: Global DNA Damage Response Drugs Market, by Commercialized Drugs,
2019-2030 ...........................................................................................................................89
Figure 10.2: Global Revenue for Lynparza, 2019-2030 ...................................................................91
Figure 10.3: Treatment Flow of Lynparza for Each Indication..........................................................92
Figure 10.4: Global Revenue for Talzenna, 2019-2030 ...................................................................93
Figure 10.5: Treatment Flow of Talzenna for Each Indication..........................................................94

13. Global DNA Damage Response Drugs Market
All rights reserved at BIS Research 13
Figure 10.6: Global Revenue for Zejula, 2019-2030 ........................................................................96
Figure 10.7: Treatment Plan of Zejula for Each Indication ...............................................................97
Figure 10.8: Global Revenue for Rubraca, 2019-2030 ....................................................................98
Figure 10.9: Treatment Plan of Rubraca for Each Indication ...........................................................99
Figure 11.1: Expected Revenue for Pamiparib (by Late Phase), 2025-2030 .................................103
Figure 11.2: Expected Revenue for Veliparib (by Late Phase), 2025-2030 ...................................104
Figure 11.3: Expected Revenue for Fluzoparib (by Late Phase), 2025-2030.................................105
Figure 12.1: Global DNA Damage Response Drugs Market (by Application) ................................112
Figure 12.2: Global DNA Damage Response Drugs Market (by Application), 2019-2030 .............113
Figure 12.3: Global DNA Damage Response Drugs Market (by Ovarian Cancer), 2019-2030......114
Figure 12.4: Global DNA Damage Response Drugs Market (by Breast Cancer), 2019-2030........118
Figure 12.5: Global DNA Damage Response Drugs Market (by Pancreatic Cancer), 2019-
2030...................................................................................................................................121
Figure 12.6: Global DNA Damage Response Drugs Market (by Prostate Cancer), 2019-
2030...................................................................................................................................123
Figure 13.1: Global DNA Damage Response Drugs Market Snapshot (by Region) ......................126
Figure 13.2: Global DNA Damage Response Drugs Market (by Region), 2019-2030 ...................127
Figure 13.3: Global DNA Damage Response Drugs Market Share (by Region), 2019 and
2030...................................................................................................................................128
Figure 13.4: North America DNA Damage Response Drugs Market, 2019-2030 ..........................130
Figure 13.5: North America: Market Dynamics ..............................................................................131
Figure 13.6: North America DNA Damage Response Drugs Market (by Country), 2019-2030......131
Figure 13.7: U.S. DNA Damage Response Drugs Market, 2019-2030..........................................133
Figure 13.8: Canada DNA Damage Response Drugs Market, 2019-2030 ....................................135
Figure 13.9: Europe DNA Damage Response Drugs Market, 2019-2030 .....................................136
Figure 13.10: Europe Market Dynamics.........................................................................................137
Figure 13.11: Europe DNA Damage Response Drugs Market (by Country), 2019-2030...............138
Figure 13.12: Germany DNA Damage Response Drugs Market, 2019-2030 ................................139
Figure 13.13: France DNA Damage Response Drugs Market, 2019-2030....................................141
Figure 13.14: U.K. DNA Damage Response Drugs Market, 2019-2030........................................142
Figure 13.15: Italy DNA Damage Response Drugs Market, 2019-2030.........................................144

14. Global DNA Damage Response Drugs Market
All rights reserved at BIS Research 14
Figure 13.16: Spain DNA Damage Response Drugs Market, 2019-2030......................................145
Figure 13.17: Switzerland DNA Damage Response Drugs Market, 2019-2030.............................147
Figure 13.18: Rest-of-Europe DNA Damage Response Drugs Market, 2019-2030.......................148
Figure 13.19: Asia-Pacific DNA Damage Response Drugs Market, 2019-2030 ............................149
Figure 13.20: APAC: Market Dynamics .........................................................................................150
Figure 13.21: APAC DNA Damage Response Drugs Market (by Country), 2019-2030.................151
Figure 13.22: China DNA Damage Response Drugs Market, 2019-2030......................................152
Figure 13.23: Japan DNA Damage Response Drugs Market, 2019-2030 .....................................154
Figure 13.24: India DNA Damage Response Drugs Market, 2019-2030 .......................................155
Figure 13.25: Australia DNA Damage Response Drugs Market, 2019-2030 .................................157
Figure 13.26: RoAPAC DNA Damage Response Drugs Market, 2019-2030.................................158
Figure 13.27: Latin America DNA Damage Response Drugs Market, 2019-2030 .........................159
Figure 13.28: Latin America: Market Dynamics .............................................................................160
Figure 13.29: Latin America DNA Damage Response Drugs Market (by Country), 2019-
2030...................................................................................................................................160
Figure 13.30: Brazil DNA Damage Response Drugs Market, 2019-2030 ......................................162
Figure 13.31: Rest-of-Latin America DNA Damage Response Drugs Market, 2019-2030.............163
Figure 13.32: RoW DNA Damage Response Drugs Market, 2019-2030.......................................164
Figure 14.1: Total Number of Companies Profiled.........................................................................165
Figure 14.2: AbbVie Inc.: Pipeline Product Portfolio.......................................................................167
Figure 14.3: AbbVie Inc.: Overall Financials, 2017-2019 ...............................................................168
Figure 14.4: AbbVie Inc.: Revenue (by Region), 2017-2019..........................................................169
Figure 14.5: AbbVie Inc.: R&D Expenditure, 2017-2019................................................................170
Figure 14.6: AbbVie Inc.: SWOT Analysis .....................................................................................171
Figure 14.7: AstraZeneca plc: Overall Product Portfolio ................................................................173
Figure 14.8: AstraZeneca plc: Pipeline Product Portfolio...............................................................174
Figure 14.9: AstraZeneca plc: Overall Financials, 2017-2019........................................................176
Figure 14.10: AstraZeneca plc: Revenue (by Segment), 2017-2019 .............................................177
Figure 14.11: AstraZeneca plc: Revenue (by Region), 2017-2019 ................................................177
Figure 14.12: AstraZeneca plc: R&D Expenditure, 2017-2019 ......................................................178
Figure 14.13: AstraZeneca plc: SWOT Analysis............................................................................179

15. Global DNA Damage Response Drugs Market
All rights reserved at BIS Research 15
Figure 14.14: Bayer AG: Pipeline Product Portfolio .......................................................................181
Figure 14.15: Bayer AG: Overall Financials, 2017-2019................................................................181
Figure 14.16: Bayer AG: Revenue (by Segment), 2018-2019 .......................................................182
Figure 14.17: Bayer AG: Revenue (by Region), 2017-2019 ..........................................................183
Figure 14.18: Bayer AG: R&D Expenditure, 2017-2019.................................................................184
Figure 14.19: Bayer AG: SWOT Analysis......................................................................................185
Figure 14.20: BeiGene, Ltd.: Pipeline Product Portfolio.................................................................187
Figure 14.21: BeiGene, Ltd.: Overall Financials: 2017-2019..........................................................188
Figure 14.22: BeiGene, Ltd.: Revenue (by Region), 2017-2019 ....................................................189
Figure 14.23: BeiGene, Ltd.: R&D Expenditure, 2017-2019 ..........................................................190
Figure 14.24: BeiGene, Ltd.: SWOT Analysis................................................................................191
Figure 14.25: Clovis Oncology: Overall Product Portfolio ..............................................................193
Figure 14.26: Clovis Oncology: Pipeline Product Portfolio.............................................................193
Figure 14.27: Clovis Oncology: Overall Financials, 2017-2019......................................................194
Figure 14.28: Clovis Oncology: R&D Expenditure, 2017-2019 ......................................................195
Figure 14.29: Clovis Oncology: SWOT Analysis............................................................................196
Figure 14.30: Debiopharm International SA: Pipeline Product Portfolio.........................................198
Figure 14.31: Debiopharm International SA: SWOT Analysis........................................................199
Figure 14.32: Eli Lilly & Company: Pipeline Product Portfolio ........................................................201
Figure 14.33: Eli Lilly & Company: Overall Financials, 2017-2019.................................................201
Figure 14.34: Eli Lilly & Company: Revenue (by Region), 2017-2019 ...........................................202
Figure 14.35: Eli Lilly & Company: SWOT Analysis.......................................................................204
Figure 14.36: GlaxoSmithKline plc: Overall Product Portfolio ........................................................206
Figure 14.37: GlaxoSmithKline plc: Pipeline Product Portfolio.......................................................206
Figure 14.38: GlaxoSmithKline plc: Overall Financials, 2017-2019................................................207
Figure 14.39: GlaxoSmithKline plc: Revenue (by Segment), 2017-2019.......................................208
Figure 14.40: GlaxoSmithKline plc: Revenue (by Region), 2017-2019..........................................209
Figure 14.41: GlaxoSmithKline plc: R&D Expenditure, 2017-2019 ................................................209
Figure 14.42: GlaxoSmithKline plc: SWOT Analysis......................................................................210
Figure 14.43: Merck KGaA: Pipeline Product Portfolio...................................................................212
Figure 14.44: Merck KGaA: Overall Financials, 2017-2019...........................................................213

16. Global DNA Damage Response Drugs Market
All rights reserved at BIS Research 16
Figure 14.45: Merck KGaA: Revenue (by Segment), 2017-2019...................................................213
Figure 14.46: Merck KGaA: Revenue (by Region), 2017-2019......................................................214
Figure 14.47: Merck KGaA: R&D Expenditure, 2017-2019............................................................215
Figure 14.48: Merck KGaA: SWOT Analysis .................................................................................216
Figure 14.49: NMS Group S.p.A: Pipeline Product Portfolio ..........................................................218
Figure 14.50: NMS Group S.p.A: SWOT Analysis.........................................................................219
Figure 14.51: Onxeo SA: Pipeline Product Portfolio ......................................................................221
Figure 14.52: Onxeo SA: Overall Financials, 2017-2019...............................................................222
Figure 14.53: Onxeo SA: Revenue (by Segment), 2017-2019.......................................................223
Figure 14.54: Onxeo SA: Revenue (by Region), 2017...................................................................223
Figure 14.55: Onxeo SA: Revenue (by Region), 2018-2019..........................................................224
Figure 14.56: Onxeo SA: R&D Expenditure (by Region), 2018-2019 ............................................224
Figure 14.57: Onxeo SA: SWOT Analysis .....................................................................................225
Figure 14.58: Pfizer Inc.: Overall Product Portfolio ........................................................................227
Figure 14.59: Pfizer Inc.: Pipeline Product Portfolio.......................................................................227
Figure 14.60: Pfizer Inc.: Overall Financials, 2017-2019................................................................228
Figure 14.61: Pfizer Inc.: Revenue (by Segment), 2017-2019 .......................................................229
Figure 14.62: Pfizer Inc.: Revenue Split (by Biopharma Segment), 2017-2019.............................230
Figure 14.63: Pfizer Inc.: Revenue (by Region), 2017-2019 ..........................................................231
Figure 14.64: Pfizer Inc.: R&D Expenditure, 2017-2019 ................................................................232
Figure 14.65: Pfizer Inc.: SWOT Analysis......................................................................................233
Figure 14.66: Repare Therapeutics: Pipeline Product Portfolio .....................................................235
Figure 14.67: Repare Therapeutics: SWOT Analysis ....................................................................236
Figure 14.68: Sierra Oncology, Inc.: Pipeline Product Portfolio......................................................238
Figure 14.69: Sierra Oncology, Inc.: Overall Financials, 2017-2019 ..............................................239
Figure 14.70: Sierra Oncology, Inc.: R&D Expenditure, 2017-2019...............................................240
Figure 14.71: Sierra Oncology, Inc.: SWOT Analysis ....................................................................241
Figure 14.72: Zentalis Pharmaceuticals, LLC: Pipeline Product Portfolio.......................................243
Figure 14.73: Zentalis Pharmaceuticals, LLC: SWOT Analysis .....................................................244

17. Global DNA Damage Response Drugs Market
All rights reserved at BIS Research 17
List of Tables
Table 4.1: Approved DNA Damage Response Drugs, May 2020....................................................45
Table 6.1: Impact Analysis of Market Drivers...................................................................................61
Table 6.2: Impact Analysis of Market Restraints..............................................................................62
Table 6.3: Comparison of R&D Expenditure of Major Companies in Global DNA Damage
Response Drugs Market, $Million, 2019 and 2018 ..............................................................65
Table 8.1: Cancer Types Treated with DNA Damage Response Drugs ..........................................80
Table 11.1: Pipeline of PARP Inhibitors in the Global DNA Damage Response Drugs Market......106
Table 11.2: Pipeline of PARP Inhibitors in the Global DNA Damage Response Drugs Market......106
Table 11.3: Pipeline of WEE1 Kinase Inhibitors in the Global DNA Damage Response Drugs
Market................................................................................................................................107
Table 11.4: Pipeline of ATR Kinase Inhibitors in the Global DNA Damage Response Drugs
Market................................................................................................................................108
Table 11.5: Pipeline of ATR Kinase Inhibitors in the Global DNA Damage Response Drugs
Market................................................................................................................................108
Table 11.6: Pipeline of Aurora B Kinase Inhibitor in the Global DNA Damage Response
Drugs Market.....................................................................................................................109
Table 11.7: Pipeline of DNA-PK Inhibitor in the Global DNA Damage Response Drugs
Market................................................................................................................................110
Table 11.8: Pipeline of DNA-PK Inhibitor in the Global DNA Damage Response Drugs
Market................................................................................................................................110
Table 11.9: Pipeline of Other Inhibitors in the Global DNA Damage Response Drugs Market.......111
Table 11.10: Pipeline of Other Inhibitors in the Global DNA Damage Response Drugs
Market................................................................................................................................111
Table 12.1: Marketed DNA Damage Response (DDR) Drugs for Ovarian Cancer........................115
Table 12.2: DNA Damage Response (DDR) Drugs for Ovarian Cancer: Pipeline Products ..........117
Table 12.3: Marketed DNA Damage Response (DDR) Drugs for Breast Cancer ..........................120
Table 12.4: DNA Damage Response (DDR) Drugs for Breast Cancer: Pipeline Products ............120
Table 12.5: Marketed DNA Damage Response (DDR) Drugs for Pancreatic Cancer....................122
Table 12.6: DNA Damage Response (DDR) Drugs for Pancreatic Cancer: Pipeline Products......123

18. Global DNA Damage Response Drugs Market
All rights reserved at BIS Research 18
Table 12.7: Marketed DNA Damage Response (DDR) Drugs for Prostate Cancer .......................124
Table 12.8: DNA Damage Response (DDR) Drugs for Prostate Cancer: Pipeline Products..........125

19. Global DNA Damage Response Drugs Market
All rights reserved at BIS Research 19
BIS Research Offerings:
We are on a mission to harness the potential of disruptive technologies to make businesses thrive in
today’s digital age. We have a vision to be a leading and a preferred knowledge partner for corporates
and institutions worldwide and assist them with market intelligence in the area of emerging
technologies, advisories, and other innovative solutions.
Know More Know More
Know More
Know More

20. Global DNA Damage Response Drugs Market
All rights reserved at BIS Research 20
Disclaimer
BIS Research provides valuable market intelligence to an exclusive group of customers in response
to orders. The report is licensed for the customer's internal use only and is subject to restrictions set
henceforth. This document and its contents are confidential and may not be further distributed,
published or reproduced, in whole or in part, by any medium or in any form for any purpose, without
the express written consent of BIS Research. Customer will not disclose the contents of the report,
whether directly in any media or indirectly through incorporation in a database, marketing list, report
or otherwise, or use or permit the use of Information to generate any statistical or other information
that is or will be provided to third parties; or voluntarily produce Information in legal proceedings.
Market reports are based on expectations, estimates and projections as of the date such information
is available. Any recommendation contained in this report may not be suitable for all investors or
businesses. The market conclusions drawn are necessarily based upon a number of estimates and
assumptions that, while considered reasonable by BIS Research as of the date of such statements,
are inherently subject to market fluctuations and business, economic and competitive uncertainties
and contingencies
For more details regarding permission, please contact us:
Email: sales@bisresearch.com
Tel: +1 510 404 8135

21. Global DNA Damage Response Drugs Market
All rights reserved at BIS Research 21
BIS RESEARCH INC.
39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686
E-mail: info@bisresearch.com | Call Us: +1-510-404-8135
Global Delivery Center
Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway,
Sector 126, Noida, U.P., 201303, India
Tel: +91 120 4261540 / 4261544
www.bisresearch.com